Sanofi: Diabetes Mellitus, Type 1 trials
The registry lists 67 Diabetes Mellitus, Type 1 studies with Sanofi as lead sponsor. 6 are open to participants now and 13 have results posted.
Phase 1 21Phase 2 6Phase 3 20Phase 4 14No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)RecruitingNCT07457580
- Long-Term Outcomes of Teplizumab in Routine Clinical CareRecruitingNCT07360080
- A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United StatesRecruitingNCT07260110
- A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesRecruitingNCT07088068Phase 3
- Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)RecruitingNCT07038473Not applicable
- Registry for Stage 2 Type 1 DiabetesRecruitingNCT06481904
- At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)CompletedNCT04270942Phase 2Results posted
- Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes PatientsCompletedNCT04075513Phase 4Results posted
- Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of TeplizumabCompletedNCT03875729Phase 3Results posted
- Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin GlargineCompletedNCT03874715Phase 3Results posted
- Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)TerminatedNCT03260868Phase 4Results posted
- Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin GlargineCompletedNCT03211858Phase 3Results posted
- Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes MellitusCompletedNCT02735044Phase 3Results posted
- A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes MellitusCompletedNCT02688933Phase 4Results posted
- Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin GlargineCompletedNCT02273180Phase 3Results posted
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes MellitusCompletedNCT01683266Phase 3Results posted
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime InsulinCompletedNCT01658579Phase 2Results posted
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 DiabetesCompletedNCT00993473Phase 3Results posted
- Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes MellitusCompletedNCT00607087Phase 4Results posted
- Description of Patients With Type 1 Diabetes Treated With TeplizumabCompletedNCT06892002
- Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® MoleculeActive, not recruitingNCT06812988Phase 2
- Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 DiabetesActive, not recruitingNCT06791291Phase 2
- Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)Active, not recruitingNCT06111586Phase 2
- Teplizumab in Pediatric Stage 2 Type 1 DiabetesCompletedNCT05757713Phase 4
- Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)Active, not recruitingNCT04598893
- Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes MellitusCompletedNCT03916601Phase 1
- A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 DiabetesCompletedNCT03903016Phase 1
- Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus PatientsCompletedNCT03436498Phase 1
- Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mLCompletedNCT03406000Phase 4
- Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of DiabetesCompletedNCT03312478Phase 4
- Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy SubjectsCompletedNCT03310944Phase 1
- A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes MellitusCompletedNCT03202875Phase 1
- A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes MellitusCompletedNCT02910518Phase 1
- A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced HypoglycemiaWithdrawnNCT02635243Phase 1
- A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus PatientsCompletedNCT02625636Phase 1
- Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin InfusionCompletedNCT02603510Phase 1
- A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 DiabetesCompletedNCT02273258Phase 1
- Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With LantusCompletedNCT02201199Phase 1
- Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes MellitusCompletedNCT01838083Phase 1
- Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes MellitusCompletedNCT01689129Phase 3
- Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes MellitusCompletedNCT01676233Phase 1
- Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes MellitusCompletedNCT01493115Phase 1
- Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes MellitusCompletedNCT01349855Phase 1
- Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.CompletedNCT01223131Phase 3
- baSal BoluS Therapy in patIenTs With TypE 1 Diabetes MellitusCompletedNCT01204593Phase 4
- Apidra Children & Adolescents StudyCompletedNCT01202474Phase 4
- Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®CompletedNCT01195454Phase 1
- Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 DiabetesCompletedNCT01194882Phase 3
- Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1CompletedNCT01146678Phase 1
- Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)CompletedNCT01053728Phase 1/2
- Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes MellitusCompletedNCT00964574Phase 4
- Glulisine + Lantus in Type I PatientsCompletedNCT00546702Phase 3
- Glulisine + Lantus in Type I PatientsCompletedNCT00545337Phase 3
- Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics StudyCompletedNCT00539448Phase 4
- 32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes MellitusCompletedNCT00537251Phase 3
- APIDRA Registration StudyCompletedNCT00489190Phase 4
- Insulin Glulisine, Diabetes Mellitus Type 1CompletedNCT00397553Phase 3
- Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)CompletedNCT00390728Phase 4
- Dose-Exposure-Response in Type 1 Diabetes MellitusCompletedNCT00368394Phase 1
- SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1CompletedNCT00313937Phase 4
- Insulin Glulisine in Type 1 Diabetes MellitusCompletedNCT00297583Phase 1
- Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes MellitusCompletedNCT00290979Phase 3
- Glulisine Pre- and PostmealCompletedNCT00290043Phase 1
- Insulin Glargine in Type 1 Diabetes MellitusCompletedNCT00272090Phase 3
- Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic PatientsCompletedNCT00271284Phase 3
- Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and AdolescentsCompletedNCT00115570Phase 3
- 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.CompletedNCT00046150Phase 3